|
|
|
| Clinical dosimetry evaluation of linear accelerator intensity-modulated radiation therapy for esophageal cancer at different sites |
| LU Dongyun YANG Jian SUN Jinyi ZHOU Jianjun YANG Jun▲ |
Department of Oncology, Haian Traditional Chinese Medicine Hospital, Jiangsu Province, Haian 226600, China
|
|
|
|
Abstract Objective To evaluate the clinical dosimetry characteristics of linear accelerator intensity-modulated radiation therapy (IMRT) for esophageal cancer at different pathological sites. Methods The clinical data of 132 patients with esophageal cancer admitted to Haian Traditional Chinese Medicine Hospital of Jiangsu Province from November 2019 to October 2021 were retrospectively analyzed, including 33 patients with cervical and upper, middle, and lower thoracic esophageal cancer. The difference of planned target dose, the dosimetric index of sketched organs at risk, machine hops, dose-validation pass rate, and treatment time of linear accelerator IMRT in patients with esophageal cancer at different sites was compared. Results The 2% of target volume exposure dose (D2), D50, D98, and mean dose (Dmean) in patients with upper and middle thoracic esophageal cancer were higher than those in cervical patients, and the treatment time was longer than that in cervical patients; target dose homogeneity index (HI) in patients with middle thoracic esophageal cancer was higher than that in cervical patients; the volume receiving a radiation dose of 25 Gy (V25), Dmean of the heart and V5, V20, V30 of both lungs in patients with upper, middle, and lower thoracic esophageal cancer were higher than those in cervical patients; the dose-validation pass rate in patients with upper and lower thoracic esophageal cancer were higher than those of cervical patients (P＜0.05). D2, HI, V25 of heart, Dmean of heart, and V5, V20, V30 of both lungs in patients middle thoracic esophageal cancer were higher than those in upper thoracic patients, and the dose-validation pass rate was lower than that in upper thoracic patients; the machine hops in patients with lower thoracic esophageal cancer were lower than those in upper thoracic patients, the treatment time was shorter than that in upper thoracic patients (P＜0.05). D2, D50, D98, Dmean, HI, and machine hops in patients with lower thoracic esophageal cancer were lower than those in middle thoracic patients, and V25, Dmean of heart, and dose-validation pass rate were higher than those in middle thoracic patients, and the treatment time was shorter than that in middle thoracic patients (P＜0.05). Conclusion The clinical dose of linear accelerator IMRT in different pathological sites of esophageal cancer is different, which should be paid attention to in clinic.
|
|
|
|
|
|
[1] 华传礼，王增才.SIB-IMRT与常规调强放射治疗食管癌的效果研究[J].武警后勤学院学报：医学版，2021，30（9）：47-48.
[2] 王佳浩，赵鹏军，徐莉霞，等.上胸段食管癌调强放射治疗中淋巴结意外照射的剂量学研究[J].中华放射医学与防护杂志，2020，40（1）：36-41.
[3] 唐涛，庞皓文，石翔翔，等.中上段食管癌调强放疗肺及心脏体积与吸收剂量数学模型建立与验证[J].中华肿瘤防治杂志，2020，27（7）：533-536.
[4] 迪丽达尔·斯地克，才层，叶建蔚，等.化疗联合调强放疗治疗食管癌的疗效及不良反应评价[J].癌症进展，2020， 18（7）：687-689.
[5] 谢晓烨，冀天楠，丛小虎，等.国产和进口医用直线加速器及治疗计划系统在肺癌调强放疗中的临床剂量学研究[J].医疗卫生装备，2022，43（2）：47-50，55.
[6] 张若辉，白文文，李润霄，等.食管癌不同直线加速器静态调强放疗的剂量学比较[J].中华肿瘤防治杂志，2017， 24（1）：38-43.
[7] 刘连科，束永前.实用食管肿瘤诊疗学[M].北京：科学出版社，2015：23-25.
[8] 赫捷，邵康.中国食管癌流行病学现状、诊疗现状及未来对策[J].中国癌症杂志，2011，21（7）：4-9.
[9] 徐轶，魏洁.非手术食管癌精确放疗靶区勾画进展[J].安徽医药，2018，22（10）：1855-1859.
[10] 张璋，范强，姚永熠，等.PET/CT在食管癌调强放疗靶区勾画中的应用探讨[J].长治医学院学报，2017，31（1）：43-47.
[11] 邓文钊，Mamady K，李曙光，等.食管癌调强放疗同期加量与序贯加量的研究[J].中华放射肿瘤学杂志，2018， 27（10）：65-69.
[12] 牛锐，胡永强.食管癌放疗应用容积旋转调强放疗技术的可行性研究[J].中国医学工程，2019，27（6）：28-30.
[13] 王佩，岳成山，王会霞，等.食管癌调强放射治疗的初期疗效及急性放射性肺损伤的影响因素分析[J].现代生物医学进展，2020，20（22）：4373-4377.
[14] 张一贺，张雁山，李小军，等.碳离子与光子容积旋转调强放射治疗胸段食管癌的剂量学对比[J].肿瘤学杂志，2022，28（1）：67-69.
[15] 袁美芳，赵彪，杨毅，等.胸中段食管癌静态调强放疗与容积旋转调强放疗的靶区及危及器官的剂量学参数比较[J].实用临床医药杂志，2020，24（15）：21-24.
[16] 牟艳红，刘强，方志祥，等.胸中段食管癌调强放疗的临床疗效分析[J].实用肿瘤杂志，2020，35（5）：450-453.
[17] 金丽媛，付春鹏，丁静静，等.基于国产和进口直线加速器实施前列腺癌调强放射治疗的临床剂量学评估[J].中国医疗设备，2021，36（4）：86-89.
[18] 张楼正，许青，胡伟刚，等.联影可旋转540°机架直线加速器在容积调强放疗计划中的效率优势分析[J].中国癌症杂志，2021，31（10）：920-926.
[19] 欧瑶，周希法，陆忠华，等.老年局部晚期食管癌患者调强放疗效果及预后分析[J].肿瘤研究与临床，2022，34（4）：276-280.
[20] 郑磊，赵胜光，许赪，等.食管鳞癌调强放疗后急性放射性肺炎发生的临床和剂量学相关因素分析[J].诊断学理论与实践，2019，25（1）：26-31.
[21] 葛曦，郑杰，杜小雷，等.调强放疗同步TP化疗对老年进展期食管癌的疗效观察及随访[J].临床和实验医学杂志，2020，19（16）：1719-1723.
[22] 沈文斌，许金蕊，李曙光，等.颈段及胸上段食管癌调强放疗不同照射方式预后分析[J].中华放射肿瘤学杂志，2020，29（10）：842-848.
[23] 娄朝阳，雷宏昌，毛荣虎，等.基于危及器官剂量预测和射野角度优化的食管癌调强放疗自动计划研究[J].中华放射肿瘤学杂志，2021，30（12）：1275-1279.
[24] 刘凌湘，易兰，黄贤海，等.铅门固定技术在全段食管癌调强放疗计划设计中的应用[J].中国医学物理学杂志，2021，38（7）：809-813.
[25] 路逵，张晶，何学军，等.脾多肽联合FP化疗方案及三维适形调强放疗治疗食管癌对患者免疫指标及骨髓抑制的影响[J].实用癌症杂志，2021，36（3）：440-442.
[26] 郭翌.食管癌肿瘤部位对调强放疗肺剂量体积参数的影响[J].中国医疗器械信息，2020，26（24）：9-11，16. |
|
|
|
